RBC Capital Sticks to Their Buy Rating for BeOne Medicines (ONC)
at www.tipranks.com (Fri, 30-Jan 8:49 PM)
FDA Accepts Summit's Lung Cancer Drug Application, Review Underway
at www.benzinga.com (Thu, 29-Jan 12:28 PM)
Zanubrutinib Update: What BeiGene’s BTK Intolerance Study Means for Oncology Investors
at www.tipranks.com (Wed, 28-Jan 11:30 AM)
Prelude Therapeutics’ PRT2527 Trial Completion: What Investors Should Watch in Hematologic Oncology
at www.tipranks.com (Mon, 26-Jan 11:31 AM)
BeiGene’s BGB-24714 Solid Tumor Trial Terminated: What It Means for Oncology Investors
at www.tipranks.com (Mon, 26-Jan 11:30 AM)
Market Chameleon (Wed, 7-Jan 9:03 AM)
BeOne Medicines to Spotlight Global Oncology Advances at 44th J.P. Morgan Healthcare Conference
Market Chameleon (Tue, 23-Dec 8:56 AM)
ZIIHERA-Based Regimens Set to Redefine First-Line HER2-Positive Gastric Cancer Treatment
Market Chameleon (Mon, 17-Nov 9:02 AM)
Market Chameleon (Thu, 6-Nov 8:47 AM)
